Valuation: Amplia Therapeutics Limited

Market Cap 64.16M 45.6M 39.85M 37.46M 34.18M 64.15M 4.36B 450M 173M 2.23B 171M 168M 7.18B P/E 2027 *
-5.43x
P/E 2028 * -17.9x
Enterprise Value 46.26M 32.88M 28.73M 27.01M 24.65M 46.26M 3.14B 324M 125M 1.61B 123M 121M 5.17B EV / Sales 2027 *
-
EV / Sales 2028 * 4.29x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -
1 day+9.90%
1 week+12.31%
Current month-8.30%
1 month-14.00%
3 months+14.62%
6 months+14.62%
Current year+16.22%
1 week 0.08
Extreme 0.0785
0.1
1 month 0.07
Extreme 0.07304
0.1
Current year 0.06
Extreme 0.057
0.27
1 year 0.05
Extreme 0.0492
0.27
3 years 0.02
Extreme 0.025
0.27
5 years 0.02
Extreme 0.025
0.27
10 years 0.01
Extreme 0.012
1.6
Manager TitleAgeSince
Chief Executive Officer - 05/12/2022
Director of Finance/CFO - 01/10/2021
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Director/Board Member 70 02/09/2015
Chairman - 25/05/2018
Chairman - 30/06/2026
Change 5-day change 1-year change 3-year change Capi.($)
+9.90%+12.31% - - 45.6M
-0.07%+7.14%+53.95%+111.00% 74.27B
-0.47%+0.40%+35.89%+78.54% 61.21B
+0.28%+5.73%+33.67%+20.82% 27.55B
-0.15%+0.75%-16.69%+361.67% 26.38B
+2.93%+4.32%+2.18%-3.60% 25.34B
+1.16%+4.03%+26.03%-8.77% 20.84B
-1.47%+4.86%-5.94%+519.63% 14.94B
+0.87%-3.73%+159.95%+327.53% 15.17B
+1.63%+2.20%+46.92%+170.72% 14.41B
Average +1.47%+3.17%+37.33%+175.28% 31.12B
Weighted average by Cap. +0.32%+3.44%+36.78%+135.97%

Financials

2027 *2028 *
Net sales - 9.5M 6.75M 5.9M 5.55M 5.06M 9.5M 645M 66.56M 25.68M 330M 25.36M 24.8M 1.06B
Net income -11.6M -8.24M -7.2M -6.77M -6.18M -11.6M -788M -81.27M -31.36M -402M -30.96M -30.28M -1.3B -4.1M -2.91M -2.55M -2.39M -2.18M -4.1M -279M -28.73M -11.08M -142M -10.94M -10.7M -459M
Net Debt -17.9M -12.72M -11.12M -10.45M -9.54M -17.9M -1.22B -125M -48.39M -621M -47.78M -46.73M -2B -23.4M -16.63M -14.53M -13.66M -12.47M -23.4M -1.59B -164M -63.26M -812M -62.46M -61.09M -2.62B
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
22/09/26 US$0.0917 +9.90% 34,000
18/09/26 US$0.0835 +6.31% 5,000
17/09/26 US$0.0785 +7.48% 108,000
16/09/26 US$0.0730 -10.55% 32,811
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1250AUD
Average target price
0.4200AUD
Spread / Average Target
+236.00%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!